Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Wave Life Sci Ord Sh (WVE)

Wave Life Sci Ord Sh (WVE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,051,072
  • Shares Outstanding, K 167,182
  • Annual Sales, $ 108,300 K
  • Annual Income, $ -97,010 K
  • EBIT $ -136 M
  • EBITDA $ -127 M
  • 60-Month Beta -1.72
  • Price/Sales 26.98
  • Price/Cash Flow N/A
  • Price/Book 22.33

Options Overview Details

View History
  • Implied Volatility 96.43% (-3.02%)
  • Historical Volatility 273.25%
  • IV Percentile 40%
  • IV Rank 25.86%
  • IV High 199.53% on 11/05/25
  • IV Low 60.46% on 01/03/25
  • Expected Move (DTE 21) 3.10 (17.00%)
  • Put/Call Vol Ratio 0.56
  • Today's Volume 2,019
  • Volume Avg (30-Day) 8,051
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 79,754
  • Open Int (30-Day) 84,746
  • Expected Range 15.15 to 21.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.28
  • Number of Estimates 7
  • High Estimate -0.18
  • Low Estimate -0.35
  • Prior Year 0.17
  • Growth Rate Est. (year over year) -264.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.93 +163.35%
on 12/03/25
21.73 -16.01%
on 12/09/25
+10.58 (+137.94%)
since 11/26/25
3-Month
6.51 +180.34%
on 11/14/25
21.73 -16.01%
on 12/09/25
+11.45 (+168.38%)
since 09/26/25
52-Week
5.28 +245.64%
on 04/09/25
21.73 -16.01%
on 12/09/25
+4.77 (+35.39%)
since 12/26/24

Most Recent Stories

More News
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 18.25 (unch)
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 18.25 (unch)
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction...

WVE : 18.25 (unch)
Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 18.25 (unch)
Wave Life Sciences: Q3 Earnings Snapshot

Wave Life Sciences: Q3 Earnings Snapshot

WVE : 18.25 (unch)
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update

WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceeding...

WVE : 18.25 (unch)
Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 18.25 (unch)
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025

Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of obesity designed to drive fat loss while preserving muscle...

WVE : 18.25 (unch)
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...

WVE : 18.25 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1...

See More

Key Turning Points

3rd Resistance Point 19.68
2nd Resistance Point 19.09
1st Resistance Point 18.67
Last Price 18.25
1st Support Level 17.66
2nd Support Level 17.07
3rd Support Level 16.65

See More

52-Week High 21.73
Last Price 18.25
Fibonacci 61.8% 15.45
Fibonacci 50% 13.51
Fibonacci 38.2% 11.56
52-Week Low 5.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar